Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD, Inc. (NSPR) is a medical device company whose news flow centers on its CGuard® Prime carotid stent system and proprietary MicroNet™ mesh technology for stroke prevention. Company press releases and SEC filings describe InspireMD as the developer of CGuard® Prime for the treatment of carotid artery stenosis, with a focus on making its products a standard approach in carotid stenting.
News about InspireMD often covers clinical milestones and peer-reviewed publications. For example, the company announced that results from its C-GUARDIANS pivotal trial of the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology, with data showing low rates of disabling stroke or myocardial infarction through 30 days and low ipsilateral stroke rates through one year. InspireMD has also highlighted external clinical evidence such as the CREST-2 study in the New England Journal of Medicine, which it views as supportive of carotid artery stenting combined with medical therapy.
Investors following NSPR can also expect updates on regulatory and commercial developments. Recent filings report FDA PMA approval for the CGuard Prime Carotid Stent System in the United States and subsequent announcements of a U.S. commercial launch. Quarterly earnings releases describe the impact of CGuard Prime on revenue and provide commentary on procedure volumes and expansion of the company’s commercial team.
Additional news items include capital-raising transactions, such as private placements and warrant exercises, as well as changes in board composition and senior medical leadership. Together, these updates give readers insight into InspireMD’s clinical progress, regulatory status, commercialization efforts, and corporate governance. This page aggregates such NSPR news so readers can review the company’s key announcements in one place.
InspireMD, Inc. (NSPR) announced promising early results from the SIBERIA trial, presented during EuroPCR on June 25, 2020. This study compares the CGuard™ Embolic Prevention System to the Acculink™ stent for carotid artery revascularization in high-risk patients. Key findings include a 78% reduction in cerebral lesion volume with CGuard™ and zero new cerebral lesions at 30 days, contrasting with six lesions in the Acculink™ group (p=0.03). The trial highlights CGuard™'s potential to redefine standards in carotid stenting, aiming for safer, less invasive options.
InspireMD (NYSE American: NSPR) has priced a public offering of 22,222,200 units at $0.45 each, aiming to raise approximately $10.0 million. Each unit includes one share of common stock and one Series F warrant for $0.495 per share. The underwriter has a 45-day option to purchase an additional 3,333,333 units for up to $1.5 million. Funds will support research, development, marketing, and general corporate purposes. The offering is expected to close on June 5, 2020, pending customary conditions.
InspireMD reported a substantial revenue increase of 149.2% for Q1 2020, totaling $1,034,000, driven mainly by strong sales of the CGuard™ Embolic Prevention System (EPS), which rose 158.2% to $971,000. The company also noted a recovery from third-party sterilizer failures that impacted previous sales. Gross profit improved to $295,000 compared to a gross loss last year, with a gross margin of 28.5%. Despite a net loss of $1,978,000, cash reserves were reported at $3,141,000. InspireMD aims to expand its product offerings and market reach.